Morgan Trefor, Lauri Jann, Bertram Denise, Anderson Adrianne
Department of Physiology, University of Melbourne, Parkville, Victoria 3010, Australia.
Am J Hypertens. 2004 Feb;17(2):118-23. doi: 10.1016/j.amjhyper.2003.09.012.
Central aortic systolic blood pressure (BP) is an important determinant of cardiac workload and cardiac hypertrophy. The relationship of central aortic systolic BP and brachial BP varies depending on the stiffness of blood vessels. It is not certain whether the different drug classes affect the brachial and aortic systolic BP in a similar manner. In a double-blind crossover study, we measured the effects of the four major drug classes compared with placebo on central aortic pressure. Central aortic pressure and various indices were determined using the Sphygmo Cor apparatus. The study was undertaken in patients aged 65 to 85 years with systolic BP >150 mm Hg at study entry. Results are reported for 32 patients who had satisfactory applanation tonometry in all five periods. Calcium channel blockers and diuretics caused a greater fall in brachial artery systolic BP than angiotensin-converting enzyme (ACE) inhibitors or beta-blocking drugs. On placebo, central aorta augmentation pressure and index were 23 mm Hg and 33.3%; on ACE inhibitors the values were 18 mm Hg and 30%; on beta-blockers, 26 mm Hg and 38.5%; on calcium channel blockers, 16 mm Hg and 28%; and on diuretics, 17 mm Hg and 28.8%. The augmentation pressure on beta-blocking drugs was greater than on the other three drug classes (P <.05), and augmentation pressures on ACE inhibitors, calcium channel blockers, and diuretics were less than on placebo (P <.05). The lowest central aortic pressures were achieved with calcium blocking drugs and diuretics. Therapy based on brachial artery recordings may thus overestimate the effect of beta-blocking drugs on central aortic systolic BP and underestimate the effectiveness of ACE inhibitors and calcium blocking drugs. The clinical importance of this discrepancy needs to be evaluated.
中心主动脉收缩压是心脏工作负荷和心肌肥厚的重要决定因素。中心主动脉收缩压与肱动脉血压的关系因血管僵硬度而异。不同类别药物是否以相似方式影响肱动脉和主动脉收缩压尚不确定。在一项双盲交叉研究中,我们测量了四类主要药物与安慰剂相比对中心主动脉压的影响。使用Sphygmo Cor设备测定中心主动脉压及各项指标。该研究纳入了年龄在65至85岁、研究入组时收缩压>150 mmHg的患者。报告了32例在所有五个阶段均获得满意压平式眼压测量结果的患者的研究结果。钙通道阻滞剂和利尿剂导致肱动脉收缩压下降幅度大于血管紧张素转换酶(ACE)抑制剂或β受体阻滞剂。服用安慰剂时,中心主动脉增强压和增强指数分别为23 mmHg和33.3%;服用ACE抑制剂时,分别为18 mmHg和30%;服用β受体阻滞剂时,分别为26 mmHg和38.5%;服用钙通道阻滞剂时,分别为16 mmHg和28%;服用利尿剂时,分别为17 mmHg和28.8%。β受体阻滞剂的增强压高于其他三类药物(P<.05),ACE抑制剂、钙通道阻滞剂和利尿剂的增强压低于安慰剂(P<.05)。钙通道阻滞剂和利尿剂使中心主动脉压降至最低。因此,基于肱动脉记录的治疗可能高估β受体阻滞剂对中心主动脉收缩压的影响,低估ACE抑制剂和钙通道阻滞剂的疗效。这种差异的临床重要性需要评估。